Want to see FR:VLA full AI Analyst Report?
VLA Stock Chart & Stats
€2.59
-€0.05(-2.40%)
At close: 4:00 PM EST
€2.59
-€0.05(-2.40%)
Day’s Range― - ―
52-Week Range€2.14 - €5.42
Previous CloseN/A
Volume233.04K
Average Volume (3M)1.29M
Market Cap
€443.20M
Enterprise Value€545.93M
Total Cash (Recent Filing)€105.27M
Total Debt (Recent Filing)€209.50M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 13, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding189,771,240
10 Day Avg. Volume925,642
30 Day Avg. Volume1,288,661
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.89
Price to Sales (P/S)3.58
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.38
Revenue Forecast (FY)€153.95M
Bulls Say, Bears Say
Bulls Say
First-in-class Lyme Vaccine EfficacyVLA15’s robust Phase III efficacy (>70%) and planned regulatory submissions by Pfizer create a unique, durable commercial opportunity. As the first Lyme vaccine in decades with broad serotype coverage across NA/EU, approval would open a large unmet market and provide a long‑lived, diversified revenue stream.
Chikungunya Rollout And Local LicensureActive Brazil vaccination campaigns and local licensure (Butantan‑chik) demonstrate execution in endemic markets and strengthen local access. Local manufacturing and validated demand reduce commercialization risk, support sustainable regional revenue, and reinforce partnership credibility for future rollouts.
Restructuring And Cost DisciplineA decisive restructuring (10–15% headcount cut; 25–35% opex reduction) plus early SG&A declines and controlled R&D spending should materially lower cash burn and improve operating leverage. If delivered, these measures extend runway and increase the odds of achieving self‑sustaining cash flows.
Bears Say
Sustained Cash Burn And LeveragePersistent negative operating and free cash flow and elevated leverage (~1.95x) shrink financial flexibility and raise refinancing or dilution risk. With a modest equity base (~€77m) and recurring losses, the company remains dependent on external financing, which can constrain strategic choices and pipeline funding.
Material Revenue And Margin DeteriorationA sharp, sustained revenue drop and steep gross‑margin deterioration reflect weakened end‑market demand and manufacturing inefficiencies. This undermines operating leverage, prolongs losses, and makes it harder to fund commercialization or R&D from internal cash, increasing structural business risk.
Regulatory/manufacturing Constraint For U.S. SupplyFDA observations limiting the Almeida site for U.S. supply create a durable operational constraint. It raises costs, causes write‑offs, and requires alternative supply solutions or approvals. Prolonged U.S. production limits would impair a core product's market access and long‑term margin recovery.
Valneva News
VLA FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest stock price was €2.13 and its highest was €5.42 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €443.20M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is Aug 13, 2026 which is in 39 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on May 13, 2026. The company reported -€0.18 earnings per share for the quarter, missing the consensus estimate of -€0.063 by -€0.117.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Overvalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.08.
How many shares outstanding does Valneva SE have?
Valneva SE has 189,771,240 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.18 in its last earnings report, missing expectations of -€0.063. Following the earnings report the stock price went up 1.897%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in FR:VLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE is a specialized biotechnology company focused on developing and bringing to market preventative vaccines for infectious diseases with significant unmet medical needs. Their commercial offerings for travelers include IXIARO, a vaccine against Japanese encephalitis, and DUKORAL, an oral vaccine designed to protect against diarrhea caused by Vibrio cholera and specific heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also progressed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva has VLA15, a Lyme disease vaccine candidate that has concluded Phase II clinical trials, and VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III evaluation. The company distributes its products across the United States, Canada, various European nations including Germany, Austria, the Nordics, and the United Kingdom, as well as other global markets. Valneva SE has established strategic partnerships, notably with Pfizer, Inc. for the joint development and commercialization of its Lyme disease vaccine, and with Instituto Butantan for the creation, manufacturing, and marketing of a single-shot chikungunya vaccine. The company was established in 1998 and operates from its headquarters in Saint-Herblain, France.
Technical Analysis
Options Prices
Currently, No data available
---